The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients

Oncol Lett
07 June 2022
https://pubmed.ncbi.nlm.nih.gov/35761946/

Tim - England: Eye cancer (2022) (LDN; low dose naltrexone)

Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

Curr Oncol Rep
01 June 2022
https://pubmed.ncbi.nlm.nih.gov/35648340/

LDN Webinar Presentation 18 May 2022: Dr Masoud Rashidi - LDN, Dosing, Fillers and Compounded Options. LDN, ULDN and Pain/Opioid Issues

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/

LDN Webinar Presentation 18 May 2022: Dr Mathewson - LDN as supportive care for Oncology and Autoimmune patients: Case Reviews

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/

LDN Webinar Presentation 18 May 2022: Dr Sato-Re - How and why I prescribe LDN in my integrative and general practice

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/

LDN Webinar 18 May 2022 (LDN; low dose naltrexone)

LDN Questions Answered Live by

Pharmacist Dr Masoud Rashidi - LDN Specialist
Dr Sato-Re
Dr Mathewson

Sponsored by Innovative Compounding Pharmacy icpfolsom.com